News about "Takeda "

Japan Approves Takeda's ORZEYFUL (Oveporexton) for Narcolepsy Type 1

Japan approves ORZEYFUL (oveporexton) as the first and only medicine targeting the underlying cause of narcolepsy type 1, following positive phase 3 results.

Takeda | 24/08/2026 | By News Bureau

India Approves Takeda's TAK-003 as First Dengue Vaccine

India approves Takeda's TAK-003 as its first dengue vaccine, offering long-term protection against dengue disease and hospitalisation amid rising dengue cases.

Takeda | 22/07/2026 | By News Bureau

Takeda and Indonesia Partner to Expand Access to Plasma-Derived Medicines

Takeda and Indonesia have partnered to strengthen healthcare resilience, expand access to plasma-derived medicines, and establish a national plasma donation ecosystem with an initial USD 30 million investment.

Takeda | 13/07/2026 | By News Bureau

Insilico Medicine and Takeda Collaborate on AI Drug Discovery

Takeda and Insilico Medicine are collaborating to advance Artificial Intelligence (AI)-powered drug discovery, leveraging the Pharma.AI platform to accelerate the development of therapeutics.

Takeda | 02/07/2026 | By News Bureau |  137

Takeda's Oveporexton Improves Daily Function in Narcolepsy Type 1

Takeda’s phase 3 data show oveporexton improved daily function, cognition, and nighttime sleep in people with narcolepsy type 1. The results support the potential of the first orexin agonist therapy, with regulatory submissions currently under review.

Takeda | 16/06/2026 | By News Bureau |  105

Denali Regains Full Rights to DNL593 After Takeda Ends Collaboration

The biotech firm will independently advance its investigational therapy for frontotemporal dementia, with Phase I/II trial results expected by 2026.

Takeda | 08/04/2026 | By News Bureau |  134

Takeda's Zasocitinib Shows Strong Skin Clearance in Psoriasis Study

Takeda reports Phase 3 data showing zasocitinib delivers rapid, durable skin clearance in psoriasis, with ~70 percent achieving sPGA 0/1 and early PASI 75 response, with a consistent safety profile.

Takeda | 30/03/2026 | By News Bureau |  224

Takeda's Oveporexton NDA Accepted by US FDA with Priority Review for Narcolepsy Type 1

FDA grants Priority Review to Takeda’s investigational orexin receptor agonist oveporexton (TAK-861) for narcolepsy type 1, with a PDUFA decision expected in Q3 this year.

Takeda | 11/02/2026 | By News Bureau |  200

Takeda Becomes a BaseLaunch Partner

BaseLaunch has added Takeda as a new pharmaceutical partner to its biotech venture incubator, expanding its network of global pharma backers supporting and funding early-stage drug development startups.

Takeda | 19/12/2025 | By News Bureau |  168

Innovent Biologics and Takeda Finalise Global Collaboration for Next-Generation IO and ADC Therapies

As part of the agreement, Takeda will pay Innovent an upfront payment of USD1.2 billion, including a USD100 million equity investment at HKD112.56 per share.

Takeda | 05/12/2025 | By Dineshwori |  204